INNOVIVA, INC. Accrued Liabilities and Other Liabilities
INNOVIVA, INC. (INVA) had Accrued Liabilities and Other Liabilities of $28.61 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-05
- 2026-06-30: Accrued Liabilities and Other Liabilities $28.61M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $21.80M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $29.47M.
- 2025-09-30: Accrued Liabilities and Other Liabilities $21.61M.
| Period end | Accrued Liabilities and Other Liabilities |
|---|---|
| 2026-06-30 | $28.61M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $21.80M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $29.47M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $21.61M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $37.98M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $30.66M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $30.00M 10-K · filed 2026-02-25 |
| 2024-09-30 | $17.60M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $17.13M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $23.75M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $19.70M 10-K · filed 2025-02-26 |
| 2023-09-30 | $24.70M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $22.50M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $24.90M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $21.21M 10-K/A · filed 2024-03-05 |
| 2022-09-30 | $15.12M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $17.14M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $8.07M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.01M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |